Compare AbbVie Inc (ABBV) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI Australia ETF — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while iShares MSCI Australia ETF trades at $28.03. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI Australia ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | EWA | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $30.26 |
52-Week Low | $184.85 | $24.95 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
EWA trades at $28.33, up 0.85% on the day, with technical indicators showing a bearish trend in moving averages and mixed signals from oscillators. The stock faces resistance near $29 and support at $28. Recent news highlights Australian economic headwinds, including missed GDP growth and regulatory changes affecting banks and property markets, which may influence EWA's performance given its exposure to Australian equities.
The outlook for EWA is cautious due to bearish technicals and macroeconomic pressures in Australia. Risks include slower economic growth and sector-specific challenges, but potential opportunities exist if market sentiment improves or if dividend policies attract income-focused investors. Investors should weigh these factors against the current neutral-to-bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
